Ramon Moreno-Luna

Dr. Ramon Moreno-Luna

Hospital Universitario Virgen Macarena, Seville, Spain
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2020 in Journal of Investigational Allergology and Clinical Immunology
Verified
Journal Article
Closed access
AIA Izquierdo-Domínguez
A Izquierdo-Domínguez
María Jesús Rojas-LechugaMaría Jesús Rojas-Lechuga
María Jesús Rojas-Lechuga
CCC Chiesa-Estomba
C Chiesa-Estomba
CCC Calvo-Henríquez
C Calvo-Henríquez
ENE Ninchritz-Becerra
E Ninchritz-Becerra
IAI Alobid
I Alobid
Since China's initial anecdotal reports of coronavirus disease 2019 (COVID-19), there have been a growing number of studies describing smell and/or taste dysfunction (STD). Objective: The aim was to investigate the frequency and severity of STD in COVID-19 patients and to evaluate the association with demographic characteristics, hospital admission, symptoms, comorbidities, and blood biomarkers. A multicenter cross-sectional study on SARS-CoV-2 positive patients (n=846) and controls (n=143) from 15 Spanish Hospitals. Data of STD with an in-person survey was collected prospectively. STD severity was categorized by visual analogue scale. STD onset time, recovery rate, time to recovery, hospital admission, pneumonia diagnosis, comorbidities, smoking and symptoms were analyzed. STD were at least 2-fold more common in COVID-19-positive compared to controls. In COVID-19-positive, hospitalized patients were older, with lower frequency of STD and recovered earlier than out-patients. Stratified analysis by severity of STD showed that more than a half of COVID-19 subjects presented severe loss of smell (53.7%) or taste (52.2%), in >90% this impairment was of both senses. In the multivariate analysis, an older age (>60yo), being hospitalized and an increased level of C-reactive protein were factors associated with a better sense of smell and/or taste. COVID-19-positive patients reported improvement of smell (45.6%) and taste (46.1%) at the time of the survey, 90.6% in less than two weeks' post-infection. STD is a common symptom in COVID-19, and mainly present in young and non-hospitalized patients. More studies are needed to evaluate the follow-up of the chemosensory impairment.

3 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
María Amparo Callejón LeblicMaría Amparo Callejón Leblic
María Amparo Callejón Leblic
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
Alfonso Del Cuvillo BernalAlfonso Del Cuvillo Bernal
Alfonso Del Cuvillo Bernal
ISABEL M REYES-TEJEROISABEL M REYES-TEJERO
ISABEL M REYES-TEJERO
MGMiguel A Garcia-Villaran
Miguel A Garcia-Villaran
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
The COVID-19 outbreak has spread extensively around the world. Loss of smell and taste have emerged as main predictors for COVID-19. The objective of our study is to develop a comprehensive machine learning (ML) modelling framework to assess the predictive value of smell and taste disorders, along with other symptoms, in COVID-19 infection. A multicenter case-control study was performed, in which suspected cases for COVID-19, who were tested by real-time reverse-transcription polymerase chain reaction (RT-PCR), informed about the presence and severity of their symptoms using visual analog scales (VAS). ML algorithms were applied to the collected data to predict a COVID-19 diagnosis using a 50-fold cross-validation scheme by randomly splitting the patients in training (75%) and testing datasets (25%). A total of 777 patients were included. Loss of smell and taste were found to be the symptoms with higher odds ratios of 6.21 and 2.42 for COVID-19 positivity. The ML algorithms applied reached an average accuracy of 80%, a sensitivity of 82%, and a specificity of 78% when using VAS to predict a COVID-19 diagnosis. This study concludes that smell and taste disorders are accurate predictors, with ML algorithms constituting helpful tools for COVID-19 diagnostic prediction.

Verified
Journal Article
Open access
PDF file
JPJose Palacios-García
Jose Palacios-García
CPCristina Porras-González
Cristina Porras-González
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
Juan Maza-SolanoJuan Maza-Solano
Juan Maza-Solano
JPJuan Polo-Padillo
Juan Polo-Padillo
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nose and paranasal sinuses characterized by the presence of nasal polyps. The symptoms produced by the presence of nasal polyps such as nasal obstruction, nasal discharge, facial pain, headache, and loss of smell cause a worsening in the quality of life of patients. The source of the nasal polyps remains unclear, although it seems to be due to a chronic inflammation process in the sinonasal mucosa. Fibroblasts, the main cells in connective tissue, are intimately involved in the inflammation processes of various diseases; to this end, we carried out a systematic review to evaluate their inflammatory role in nasal polyps. Thus, we evaluated the main cytokines produced by nasal polyp-derived fibroblasts (NPDF) to assess their involvement in the production of nasal polyps and their involvement in different inflammatory pathways. The results of the review highlight the inflammatory role of NPDF through the secretion of various cytokines involved in the T1, T2, and T3 inflammatory pathways, as well as the ability of NPDF to be stimulated by a multitude of substances. With these findings, the fibroblast is positioned as a new potential therapeutic target in the treatment of CRSwNP.

17 August 2022 in Life
Verified
Journal Article
Open access
PDF file
María Amparo Callejón LeblicMaría Amparo Callejón Leblic
María Amparo Callejón Leblic
Daniel I Martín-JiménezDaniel I Martín-Jiménez
Daniel I Martín-Jiménez
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
JPJose Palacios-García
Jose Palacios-García
MAMarta Alvarez-Cendrero
Marta Alvarez-Cendrero
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
Background: Although smell and taste disorders are highly prevalent symptoms of COVID-19 infection, the predictive factors leading to long-lasting chemosensory dysfunction are still poorly understood. Methods: 102 out of 421 (24.2%) mildly symptomatic COVID-19 patients completed a second questionnaire about the evolution of their symptoms one year after the infection using visual analog scales (VAS). A subgroup of 69 patients also underwent psychophysical evaluation of olfactory function through UPSIT. Results: The prevalence of chemosensory dysfunction decreased from 82.4% to 45.1% after 12 months, with 46.1% of patients reporting a complete recovery. Patients older than 40 years (OR = 0.20; 95% CI: [0.07, 0.56]) and with a duration of loss of smell longer than four weeks saw a lower odds ratio for recovery (OR = 0.27; 95% CI: [0.10, 0.76]). In addition, 28 patients (35.9%) reported suffering from parosmia, which was associated with moderate to severe taste dysfunction at the baseline (OR = 7.80; 95% CI: [1.70, 35.8]). Among the 69 subjects who underwent the UPSIT, 57 (82.6%) presented some degree of smell dysfunction, showing a moderate correlation with self-reported VAS (r = −0.36, p = 0.0027). Conclusion: A clinically relevant number of subjects reported persistent chemosensory dysfunction and parosmia one year after COVID-19 infection, with a moderate correlation with psychophysical olfactory tests.

1 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Daniel I Martín-JiménezDaniel I Martín-Jiménez
Daniel I Martín-Jiménez
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
María Amparo Callejón LeblicMaría Amparo Callejón Leblic
María Amparo Callejón Leblic
Alfonso Del Cuvillo BernalAlfonso Del Cuvillo Bernal
Alfonso Del Cuvillo Bernal
CECharles S Ebert
Charles S Ebert
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
(1) Background: Surgical criteria for chronic rhinosinusitis with nasal polyps (CRSwNP) remain unresolved. This study addresses these discrepancies by comparing the clinical outcomes of expanded–functional endoscopic sinus surgeries (E–FESS) with more-limited FESS (L-FESS). (2) Methods: A database was analyzed retrospectively to compare surgical outcomes in CRSwNP patients who underwent E-FESS versus those subjected to L-FESS. Quality of life, endoscopic and radiological outcomes were compared at the baseline and two years after surgery. The clinical status of the responder was defined when a minimal clinically important difference of 12 points in SNOT-22 change was achieved. (3) Results: A total of 274 patients met the inclusion criteria and were analyzed; 111 underwent E-FESS and 163 were subjected to L-FESS. Both groups exhibited significant clinical improvements, although a greater magnitude of change in SNOT-22 (14.8 ± 4.8, p = 0.002) was shown after E-FESS. Higher significant improvements for endoscopic and radiological scores and lower surgical revision rates were also noted in the E-FESS group. (4) Conclusions: E-FESS provides better clinical outcomes and reduced revision surgery rates when compared to L-FESS in CRSwNP patients two years after surgery, irrespective of any comorbidity. Further randomized prospective studies are needed to comprehensively contrast these results.

10 May 2024 in Sleep Science
Verified
Journal Article
Open access
PDF file
ECEduardo Javier Correa
Eduardo Javier Correa
Diego Marcelo ContiDiego Marcelo Conti
Diego Marcelo Conti
Ramon Moreno-LunaRamon Moreno-Luna
Ramon Moreno-Luna
Serafín Sánchez-GómezSerafín Sánchez-Gómez
Serafín Sánchez-Gómez
Carlos O'Connor-ReinaCarlos O'Connor-Reina
Carlos O'Connor-Reina
Objective To perform a systematic review to determine if isolated nasal surgery has any impact on subjective or objective parameters in adult obstructive sleep apnea (OSA) patients. Materials and Methods From December 2022 to March 2023, we conducted a search on the PubMed, Cochrane, Scopus, and Web of Science databases. Two independent investigators performed a study selection according to the established criteria, as well as data collection, including the study design, the subjective and objective parameters addressed, the type of intervention, and the outcomes, considering the methodological quality and risk of bias. Results In total, 25 studies met the selection criteria, and they showed that there is a significant improvement in sleep quality, sleepiness, nasal resistance, and snoring after isolated nasal surgery. Still, there is no relevant modification of other polysomnographic parameters. It also reduces the required titration pressures of continuous positive airway pressure (CPAP) and increases the duration of its use. Conclusion Isolated nasal surgery is not a primary treatment for OSA. Still, it improves the subjective parameters and can lead to CPAP therapy success by enhancing its effectiveness and long-term compliance.